CA50
Zecen
DR1017
| Quantity: | |
|---|---|
[INTENDED USE]
The kit has been designed for the quantitative determination of Carbohydrate Antigen 50 (CA50) in human serum.
The method can be used for samples over the range of 1.0~140.0 U/mL
Cancer-associated carbohydrate antigen 50 (CA50) is a ganglioside glycoprotein and is a biomarker for the diagnosis and prognosis of gastrointestinal malignancies, especially of pancreatic and colorectal cancers .
The expression level of CA50 has been measured for pancreatic and colorectal cancers and also for other cancers such as breast, lung, renal, prostatic, and ovarian cancers [6]. In addition, it can distinguish the patients of benign disease of atrophic gastritis, pancreatitis, ulcerative colitis, pneumonia, cirrhosis, and autoimmune diseases from healthy persons . The monoclonal antibody that defines CA50 reacts with both the afucosyl form of sialylated Lewis A carbohydrate moiety and sialylated Lewis A moiety on the cancer cell surface . CA50 epitope is assumed to be similar to CA19-9 epitope (sialyl-Lewis A). In fact, both CA19-9 and CA50 are valuable markers for the differentiation of pancreatic cancer from benign diseases of the pancreatobiliary tract . However, in contrast to the limited expression of CA 19-9 in gastrointestinal malignancy, high CA50 levels can also be seen in malignant tumors outside the digestive tract.
[INTENDED USE]
The kit has been designed for the quantitative determination of Carbohydrate Antigen 50 (CA50) in human serum.
The method can be used for samples over the range of 1.0~140.0 U/mL
Cancer-associated carbohydrate antigen 50 (CA50) is a ganglioside glycoprotein and is a biomarker for the diagnosis and prognosis of gastrointestinal malignancies, especially of pancreatic and colorectal cancers .
The expression level of CA50 has been measured for pancreatic and colorectal cancers and also for other cancers such as breast, lung, renal, prostatic, and ovarian cancers [6]. In addition, it can distinguish the patients of benign disease of atrophic gastritis, pancreatitis, ulcerative colitis, pneumonia, cirrhosis, and autoimmune diseases from healthy persons . The monoclonal antibody that defines CA50 reacts with both the afucosyl form of sialylated Lewis A carbohydrate moiety and sialylated Lewis A moiety on the cancer cell surface . CA50 epitope is assumed to be similar to CA19-9 epitope (sialyl-Lewis A). In fact, both CA19-9 and CA50 are valuable markers for the differentiation of pancreatic cancer from benign diseases of the pancreatobiliary tract . However, in contrast to the limited expression of CA 19-9 in gastrointestinal malignancy, high CA50 levels can also be seen in malignant tumors outside the digestive tract.
